3BNC117 is one of the most effective broad-spectrum HIV neutralizing
antibodies. Several phase 1 and phase 2 clinical trials have been conducted in
the US, showing 3BNC117 not only blocks viral replication like other AIDS
drugs, but also induces immune response to HIV and HIV-infected cells. Combining 3BNC117 with ALBUVIRTIDE, we will form an all-injectable,
long-acting, two-drug regimen that has novel mechanism of action. We plan to
initiate clinical trials in 2018 to test its safety, effectiveness, and
potential in eliciting immune response to HIV infection.
